Still betting on Nvidia? Our AI picked this stock instead; it’s up 96%+ THIS MONTH
MINNEAPOLIS - DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a biopharmaceutical company with a market capitalization of $283 million and impressive 127% return over the past year, has published a study outlining the action mechanism of its drug candidate DM199 in treating acute ischemic stroke (AIS). According to InvestingPro data, the company’s stock is trading near its 52-week high of $6.82, reflecting strong investor confidence in its development pipeline. The peer-reviewed article, now available online, will be printed in the February 2025 issue of Stroke.
The study focuses on DM199 (rinvecalinase alfa), a recombinant human tissue kallikrein-1, and its role in the company’s Phase 2/3 ReMEDy2 trial for AIS. The drug is designed to enhance collateral circulation, stimulate angiogenesis, and promote cellular repair mechanisms. While the company maintains strong financial health with a current ratio of 11.81 and minimal debt, InvestingPro analysis indicates it remains in development stage with negative EBITDA of $24 million. According to the research, DM199 can induce potent vasodilation and improve brain perfusion, potentially reducing the risk of stroke recurrence with an extended course of therapy.
The ReMEDy2 trial is a randomized, double-blind, placebo-controlled study aiming to enroll up to 728 patients at 100 global sites. It excludes patients eligible for mechanical thrombectomy but includes those experiencing persistent neurological deficits post-thrombolytic treatment.
Lead author Scott Kasner, MD, from the University of Pennsylvania, highlighted the prior Phase 2 ReMEDy1 trial’s favorable impact on AIS clinical outcomes for patients ineligible for mechanical thrombectomy. The new publication provides insights into how DM199 might improve clinical outcomes in AIS by enhancing blood flow in stroke treatment.
DM199’s role in AIS involves dilating arterioles surrounding the vascular occlusion site and inhibiting apoptosis, while promoting angiogenesis for neuronal remodeling.
DiaMedica Therapeutics is focused on developing treatments for severe ischemic diseases, including AIS and preeclampsia. DM199, their lead candidate, is the first synthetic form of the KLK1 protein, used therapeutically in Asia for AIS, preeclampsia, and other vascular diseases.
This information is based on a press release statement from DiaMedica Therapeutics Inc. and does not reflect an endorsement of the drug’s efficacy or safety. The company’s forward-looking statements are subject to risks and uncertainties, including those related to clinical trial outcomes and regulatory approvals. Analyst consensus remains optimistic, with price targets ranging from $6 to $11 per share. For deeper insights into DMAC’s financial health, valuation metrics, and growth potential, access the comprehensive Pro Research Report available exclusively on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.